Each year, Nature Biotechnology highlights companies that received sizeable early-stage funding in the previous year. Red Queen Therapeutics is combating infectious diseases with peptide viral fusion inhibitors.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Kilby, J. M. et al. AIDS Res. Hum. Retroviruses 18, 685–693 (2002).
Kottilil, S. et al. In ASM Microbe 2024 https://redqueentx.com/posters/2024-June-RQ-ASM-POSTER.pdf (2024).
Romano, J. et al. AIDS Res. Hum. Retroviruses 25, 483–488 (2009).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marchal, I. Editor’s pick: Red Queen Therapeutics. Nat Biotechnol 43, 1905–1906 (2025). https://doi.org/10.1038/s41587-025-02922-3
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41587-025-02922-3
